Our pilot study about cardiovascular abnormalities among adolescents and young adults with sickle cell disease is out. Read it here.
nature.com/articles/s41598-0…
Gene therapy cut mean annual bleeding from 13.9 to 0.5 in 11 adolescents with haemophilia B; mean factor IX activity reached 41.8 IU/dL at week 52. Promising, but this was a single-arm phase 1 trial: durability and rare harms remain unknown. doi.org/10.1038/s41591-026-0…
14
CT pulmonary angiography was avoided in 22% of patients with cancer and suspected PE. The 698-patient Hydra trial found YEARS non-inferior to CTPA-only management; 90-day failure was 1.8% vs 5.5%. Validation in African pathways is still needed. doi.org/10.1001/jama.2026.10…
32
More expensive did not mean more remission. In MAINRITSEG, 98 adults with EGPA spent 91.1 weeks in remission on rituximab vs 96.0 on azathioprine over 28 months; rituximab was not superior. Comparative trials should shape formularies. doi.org/10.1001/jama.2026.15…
1
116
In Jinja, 20 mg daily zinc reduced infections in 100 children under 5 with sickle cell anaemia: 305.7 vs 480.7 per 100 person-years over 6 months. ZIPS-2 is encouraging; one small, single-site trial should inform—not settle—policy. doi.org/10.1001/jama.2026.14…
43
AI support did not reduce 14-day treatment failure in Kenyan primary care. The pragmatic trial covered >9,000 consultations across 16 facilities and found no safety signal. For hospitals, the endpoint is patient outcomes—not polished documentation. doi.org/10.1038/s41591-026-0…
37
A useful test for any hospital innovation: What outcome should change, by how much, and by when? Then ask who owns implementation after the trial team leaves. Evidence on deprescribing, diagnostics and AI points to the same lesson: workflow determines whether tools become care.
58
An open-source AI “co-scientist” completed five biomedical analyses with externally testable findings. Roberts et al. report speed and auditability, not better patient outcomes. Hospitals need validation, governance and secure data before clinical use. doi.org/10.1038/s41591-026-0…
2
68
Five days of 40-Hz brain stimulation improved consciousness scores more than 4-Hz or sham in a randomized trial of prolonged disorders of consciousness. Promising neurophysiology; one short study cannot establish routine rehabilitation benefit.
sciencedirect.com/science/ar…
1
70
A blood test tracked advanced tau pathology—but is not a dementia screening test. In 728 participants, Brum et al.’s plasma eMTBR-tau assay aligned with neuropathology and tau-PET stages. Cross-sectional evidence needs clinical validation. doi.org/10.1001/jama.2026.25…
1
61
ctDNA surveillance doubled curative-intent treatment among colorectal cancer recurrences: 48.1% vs 23.6%. FIND randomized 584 eligible patients; recurrence itself was similar at 18.0% vs 18.6%. Survival benefit remains unproven. doi.org/10.1200/JCO-25-03009
51
Rituximab added no proteinuria or kidney-function benefit in IgA nephropathy. RITA randomized 106 adults already receiving optimized renin–angiotensin blockade; 12-month proteinuria was similar. A negative trial can prevent costly therapeutic drift.
ajkd.org/article/S0272-6386(…
59
Dapagliflozin modestly improved kidney-function trajectory after heart transplantation. DAPARHT randomized 430 recipients: 12-month eGFR change was 2.0 vs 0.3 mL/min/1.73m². Useful physiology, but the difference was small and follow-up short. doi.org/10.1161/CIRCULATIONA…
3
234
Post-hospital mobility did not improve with booklets, videos, staff training and ward posters. INTOMOB randomized 383 older adults across 12 Swiss ward clusters; the 30-day difference was 0.67 points. Low-intensity education alone may be insufficient. doi.org/10.1001/jamanetworko…
56
Cannabidiol did not improve severe behavioural problems in youths with intellectual disability. Efron et al. randomized 131 participants aged 6–18; adverse events occurred in 63.1% vs 60.6% on placebo. Popularity is not evidence. doi.org/10.1001/jamapediatri…
1
120
Before adopting an innovation, ask four questions: Does it improve a patient outcome? Compared with what? At what total cost? Can the effect be sustained in our workflow? Today’s trials show why hospitals need evidence, implementation ownership and measurement—not novelty alone.
1
2
188
Empirical TB treatment did not reduce mortality in infants with HIV and severe pneumonia. EMPIRICAL analyzed 558 infants across 19 African hospitals. Domínguez-Rodríguez et al. support guided diagnosis over automatic six-month treatment.
thelancet.com/journals/lance…
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
LET US STAND WITH OUR JUNIOR COLLEAGUE, DR. KATENDE FREDRICK
The Association of Anesthesiologists of Uganda (AAU) calls upon colleagues, friends, partners and the general public to support Dr. Katende Fredrick in his urgent fight against end-stage kidney disease.
Our colleague urgently needs a kidney transplant, and every contribution brings him closer to receiving this life-saving treatment.
Please support him through the contribution channels provided on the flyer. Every amount counts. Every act of kindness matters.
Together, we can make a difference and help save a life.
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
Our paper on 10 year CVD Mortality @MulagoReferral has been published in the @BMJ_Open .
There is rising mortality trends and women > 50 yrs have 33% increased risk compoared to those of 30yrs.
We need to pay attention to NCDs!
@mulagostarr @JC_by_AMS @Tracy_Rabin @Internist_02
Abdul M. Ssekandi, MBChB, MSc., M.A.P.S retweeted
Here is the link:
bmjopen.bmj.com/content/16/1…
#ODONGCHRISTOPHER
🤖 Made with AI





